{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447623508
| IUPAC_name = 4-<nowiki/>{(1''R'',2''R'',3a''S'',8b''S'')-2-Hydroxy-1-[(1''E'',3''S'')-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1''H''-benzo[''b'']cyclopenta[''d'']furan-5-yl}butanoic acid
| image = Structure of Beraprost.png
| width = 200

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|beraprost}}
| pregnancy_category =  
| legal_status =
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 50–70%
| metabolism = Unknown
| elimination_half-life = 35–40 minutes
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 88430-50-6
| CAS_supplemental = {{CAS|88475-69-8}}
| ATC_prefix = B01
| ATC_suffix = AC19
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1207745
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5293169
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CTPOHARTNNSRSR-APJZLKAGSA-N
| PubChem = 6917951
| IUPHAR_ligand = 1967
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 35E3NJJ4O6

<!--Chemical data-->
| C=24 | H=30 | O=5 
| molecular_weight = 398.492 g/mol
| smiles = CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
}}

'''Beraprost''' is a pharmaceutical drug used in several Asian countries, including Japan and South Korea, as a [[vasodilator]] and antiplatelet agent.<ref name=drugs>{{Cite web | url = http://www.drugs.com/international/beraprost.html | title = Beraprost | publisher = [[drugs.com]]}}</ref>  It is classified as a [[prostacyclin]] analog.<ref name=drugs/><ref>{{Cite journal | journal = Drugs | date = 2002 | volume = 62 | issue = 1 | pages = 107–33 | title = Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension | author = Melian EB, Goa KL | doi=10.2165/00003495-200262010-00005}}</ref>

It has been studied for the treatment of [[pulmonary hypertension]] and for use in avoiding [[reperfusion injury]].

==Clinical pharmacology==
As an analog of prostacyclin PGI<sub>2</sub>, beraprost affects [[vasodilation]], which in turn lowers [[blood pressure]]. Beraprost also inhibits [[platelet]] aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

==Dosage and administration==
Beraprost is administered orally as a pill available in strength of 20 mcg.  Dose ranges from 60 to 180 mcg in divided doses after meals.

==References==
{{reflist}}


{{Antithrombotics}}
{{PAH rx}}
{{Prostaglandins}}
{{Prostanoidergics}}

[[Category:Prostaglandins]]
[[Category:Alkynes]]
[[Category:Alkene derivatives]]
[[Category:Secondary alcohols]]